Adaptive Biotechnologies Corp (NASDAQ: ADPT) is 13.88% higher on its value in year-to-date trading and has touched a low of $2.28 and a high of $6.70 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ADPT stock was last observed hovering at around $4.69 in the last trading session, with the day’s gains setting it 0.89%.
Currently trading at $5.58, the stock is 6.17% and 11.99% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 4.0 million and changing 18.98% at the moment leaves the stock 39.21% off its SMA200. ADPT registered 27.69% gain for a year compared to 6-month gain of 52.88%. The firm has a 50-day simple moving average (SMA 50) of $4.9628 and a 200-day simple moving average (SMA200) of $3.999425.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 25.39% loss in the last 1 month and extending the period to 3 months gives it a 20.26%, and is 19.23% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 9.54% over the week and 8.78% over the month.
Adaptive Biotechnologies Corp (ADPT) has around 709 employees, a market worth around $883.80M and $177.28M in sales. Profit margin for the company is -110.13%. Distance from 52-week low is 144.74% and -16.72% from its 52-week high. The company has generated returns on investments over the last 12 months (-44.55%).
with sales reaching $45.84M over the same period.The EPS is expected to grow by 28.53% this year, but quarterly earnings will post 4.34% year-over-year. Quarterly sales are estimated to grow 0.13% in year-over-year returns.
Adaptive Biotechnologies Corp (ADPT) Top Institutional Holders
251.0 institutions hold shares in Adaptive Biotechnologies Corp (ADPT), with institutional investors hold 95.82% of the company’s shares. The shares outstanding are 145.08M, and float is at 142.73M with Short Float at 6.28%. Institutions hold 93.97% of the Float.
The top institutional shareholder in the company is VIKING GLOBAL INVESTORS LP with over 29.99 million shares valued at $108.58 million. The investor’s holdings represent 20.5736% of the ADPT Shares outstanding. As of 2024-06-30, the second largest holder is RUBRIC CAPITAL MANAGEMENT LP with 14.0 million shares valued at $50.68 million to account for 9.603 of the shares outstanding. The other top investors are BLACKROCK INC. which holds 11.66 million shares representing 8.0007% and valued at over $42.22 million, while MATRIX CAPITAL MANAGEMENT COMPANY, LP holds 7.938 of the shares totaling 11.57 million with a market value of $41.89 million.
Adaptive Biotechnologies Corp (ADPT) Insider Activity
The most recent transaction is an insider sale by PISKEL KYLE, the company’s Chief Financial Officer. SEC filings show that PISKEL KYLE sold 248 shares of the company’s common stock on Nov 18 ’24 at a price of $4.98 per share for a total of $1235.0. Following the sale, the insider now owns 0.15 million shares.
Adaptive Biotechnologies Corp disclosed in a document filed with the SEC on Aug 22 ’24 that Taylor Stacy L (SVP and General Counsel) sold a total of 26,922 shares of the company’s common stock. The trade occurred on Aug 22 ’24 and was made at $4.50 per share for $0.12 million. Following the transaction, the insider now directly holds 0.14 million shares of the ADPT stock.
Still, SEC filings show that on Aug 22 ’24, STACY L TAYLOR (Officer) Proposed Sale 26,922 shares at an average price of $4.50 for $0.12 million. The insider now directly holds shares of Adaptive Biotechnologies Corp (ADPT).
